← All trials
NCT06147050
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Oct 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Nov 27, 2023
- Last posted
- Nov 27, 2023
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Purpose Life SciencesLead sponsor
- Trust for Vaccines and Immunization, PakistanLead sponsor
- Trust for Vaccines and Immunization, PakistanSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.